News
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.
The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...
A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...
According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...
GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...
A new oral drug may be able to treat type 2 diabetes and obesity without impacting muscle mass as an alternative to GLP-1 ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...
Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results